Febuxostat - Generic Drug Details

What are the generic drug sources for febuxostat and what is the scope of freedom to operate?

Febuxostat is the generic ingredient in two branded drugs marketed by Alembic, Alkem Labs Ltd, Aurobindo Pharma Ltd, Dr Reddys, Hikma, Lupin Ltd, Macleods Pharms Ltd, MSN, Pharmobedient, Prinston Inc, Regcon Holdings, Sun Pharm, Sunshine, Torrent, Zydus Lifesciences, and Takeda Pharms Usa, and is included in sixteen NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Febuxostat has thirteen patent family members in eleven countries.

There are twenty-six drug master file entries for febuxostat. Twenty-two suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for febuxostat

International Patents:	13
US Patents:	2
Tradenames:	2
Applicants:	16
NDAs:	16
Drug Master File Entries:	26
Finished Product Suppliers / Packagers:	22
Raw Ingredient (Bulk) Api Vendors:	101
Clinical Trials:	104
Patent Applications:	2,289
Drug Prices:	Drug price trends for febuxostat
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for febuxostat
What excipients (inactive ingredients) are in febuxostat?	febuxostat excipients list
DailyMed Link:	febuxostat at DailyMed

See drug prices for febuxostat

Recent Clinical Trials for febuxostat

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Jiangsu HengRui Medicine Co., Ltd.	PHASE2
Shengjing Hospital	NA
XueMei Guo	NA

See all febuxostat clinical trials

Generic filers with tentative approvals for FEBUXOSTAT

Applicant	Application No.	Strength	Dosage Form
		80MG	TABLET;ORAL
		40MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for febuxostat

Drug Class	Xanthine Oxidase Inhibitor
Mechanism of Action	Xanthine Oxidase Inhibitors

Medical Subject Heading (MeSH) Categories for febuxostat

Gout Suppressants

Anatomical Therapeutic Chemical (ATC) Classes for febuxostat

M04AA	Preparations inhibiting uric acid production
M04A	ANTIGOUT PREPARATIONS
M04	ANTIGOUT PREPARATIONS
M	Musculo-skeletal system

Paragraph IV (Patent) Challenges for FEBUXOSTAT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ULORIC	Tablets	febuxostat	40 mg and 80 mg	021856	10	2013-02-13

US Patents and Regulatory Information for febuxostat

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Regcon Holdings	FEBUXOSTAT	febuxostat	TABLET;ORAL	210292-001	Dec 30, 2019	AB	RX	No	No
Pharmobedient	FEBUXOSTAT	febuxostat	TABLET;ORAL	205385-001	Jul 1, 2019		DISCN	No	No
Takeda Pharms Usa	ULORIC	febuxostat	TABLET;ORAL	021856-002	Feb 13, 2009	AB	RX	Yes	Yes
Dr Reddys	FEBUXOSTAT	febuxostat	TABLET;ORAL	205374-002	Oct 22, 2020	AB	RX	No	No
Takeda Pharms Usa	ULORIC	febuxostat	TABLET;ORAL	021856-002	Feb 13, 2009	AB	RX	Yes	Yes

Expired US Patents for febuxostat

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Usa	ULORIC	febuxostat	TABLET;ORAL	021856-001	Feb 13, 2009
Takeda Pharms Usa	ULORIC	febuxostat	TABLET;ORAL	021856-002	Feb 13, 2009
Takeda Pharms Usa	ULORIC	febuxostat	TABLET;ORAL	021856-002	Feb 13, 2009
Takeda Pharms Usa	ULORIC	febuxostat	TABLET;ORAL	021856-001	Feb 13, 2009
Takeda Pharms Usa	ULORIC	febuxostat	TABLET;ORAL	021856-001	Feb 13, 2009

EU/EMA Drug Approvals for febuxostat

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Krka, d.d., Novo mesto	Febuxostat Krka	febuxostat	EMEA/H/C/004773Febuxostat Krka is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).Febuxostat Krka is indicated in adults.	Authorised	yes	no	no	2019-03-28
Mylan Pharmaceuticals Limited	Febuxostat Mylan	febuxostat	EMEA/H/C/004374Febuxostat Mylan is indicated for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome (TLS).Febuxostat Mylan is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).Febuxostat Mylan is indicated in adults.	Authorised	yes	no	no	2017-06-15
Menarini International Operations Luxembourg S.A. (MIOL)	Adenuric	febuxostat	EMEA/H/C/00077780 mg strength:Treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).Adenuric is indicated in adults.120 mg strength:Adenuric is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).Adenuric is indicated for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome (TLS).Adenuric is indicated in adults.	Authorised	no	no	no	2008-04-21

International Patents for febuxostat

Country	Patent Number	Title	Estimated Expiration
Russian Federation	2013109380	СПОСОБ СОПУТСТВУЮЩЕЙ ТЕРАПИИ С ПРИМЕНЕНИЕМ ТЕОФИЛЛИНА И ФЕБУКСОСТАТА
Australia	2011299153	Methods for concomitant treatment of theophylline and febuxostat
Japan	2013539747
European Patent Office	2613780	MÉTHODES DE TRAITEMENT SIMULTANÉ À BASE DE THÉOPHYLLINE ET DE FÉBUXOSTAT (METHODS FOR CONCOMITANT TREATMENT OF THEOPHYLLINE AND FEBUXOSTAT)
Hong Kong	1189170	茶碱和非布索坦的聯合治療方法 (METHODS FOR CONCOMITANT TREATMENT OF THEOPHYLLINE AND FEBUXOSTAT)

Supplementary Protection Certificates for febuxostat

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1020454	CR 2010 00015	Denmark		PRODUCT NAME: FEBUXOSTAT; REG. NO/DATE: EU/1/08/447/001-004 20080421
1020454	PA2010005	Lithuania		PRODUCT NAME: FEBUXOSTATUM; REGISTRATION NO/DATE: EU/1/08/447/001-EU/1/08/447/004 20080421
1020454	SPC/GB10/019	United Kingdom		SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB10/019 GRANTED TO TEIJIN LIMITED IN RESPECT OF THE PRODUCT FEBUXOSTAT, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6408 DATED 14/03/2012 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 22/04/2023.
1020454	10C0022	France		PRODUCT NAME: FEBUXOSTAT; REGISTRATION NO/DATE: EU/1/08/447/001-004 20080421
1020454	19/2010	Austria		PRODUCT NAME: FEBUXOSTAT IN DER KRISTALLFORM A; REGISTRATION NO/DATE: EU/1/08/447/001-004 20080421

Market Dynamics and Financial Trajectory for FEBUXOSTAT

Last updated: December 31, 2025

Executive Summary

Febuxostat, marketed under brand names such as Uloric, is a xanthine oxidase inhibitor used to lower uric acid levels in patients with gout and hyperuricemia. Since its approval in 2009 in the US and subsequent global introduction, febuxostat has experienced variable market performance influenced by regulatory challenges, competition, and evolving clinical evidence. This comprehensive analysis evaluates the drug's current market positioning, growth drivers, obstacles, and future financial prospects by examining regulatory developments, competitive landscape, epidemiological trends, and emerging scientific insights.

---

What Is Febuxostat and How Does It Fit in the Pharmaceutical Market?

Attribute	Details
Therapeutic Class	Xanthine oxidase inhibitor
Indications	Gout, hyperuricemia
Mechanism of Action	Inhibits xanthine oxidase enzyme, reducing uric acid production
Market Approval Date	US FDA: 2009; EU EMA: 2010
Manufacturers	Takeda Pharmaceutical (original), subsequent generic entrants (e.g., Sandoz, Apotex)

Clinical and Regulatory Landscape

Febuxostat’s clinical efficacy surpasses or equals that of allopurinol, its primary competitor, with a notable safety profile. Regulatory scrutiny intensified after 2019 following the FDA's boxed warning regarding cardiovascular risk; similar alerts were issued by the EMA. These safety signals led to cautious prescribing practices and impacted sales trajectories.

---

Current Market Size and Geographic Distribution

Region	Market Share	Estimated Revenues (2022, USD millions)	Notes
North America	60%	$400–$500	Largest market; influenced by regulatory adjustments
Europe	20%	$130–$180	Lower uptake due to safety concerns
Asia-Pacific	15%	$80–$120	Growing, driven by rising gout prevalence
Rest of World	5%	$20–$30	Emerging markets; limited reimbursement policies

Total global revenue for febuxostat estimated at ~$600 million in 2022, with projections to decline modestly due to safety concerns and competition.

---

Drivers of Market Growth

1. Epidemiological Trends

• Rising gout prevalence: Estimated global gout prevalence increased from 1% to 4% over the last decade, with higher incidence in aging populations.
• Increasing acknowledgment of hyperuricemia as a cardiovascular risk factor, prompting wider therapeutic use.

2. Technological and Pharmaceutical Advances

• Pharmacogenomic insights: Identifying patient subgroups with better response or safety profiles.
• Formulations and delivery: Exploring alternative dosages and combination therapies to improve adherence.

3. Healthcare Policy and Reimbursement

• Favorable reimbursement policies in some regions for gout management support access, though safety alerts have tempered claims by payers.

4. Competitive Positioning

• Despite safety issues, febuxostat’s efficacy sustains its role where allopurinol is contraindicated or poorly tolerated.

---

Barriers and Challenges

1. Safety Concerns and Regulatory Restrictions

• 2019 FDA Black Box Warning: Risk of cardiovascular death, leading to reduced prescriptions, especially for high-risk patients.
• EU and other markets: Followed the US trend, decreasing market share.

2. Competition from Existing and Emerging Therapies

Competitors	Key Features	Market Share Impact
Allopurinol	Cost-effective, longstanding use	Dominant, but with tolerability issues
Febuxostat (Generic) Versions	Lower priced, patient-specific formulations	Increased price competition, reduced margins
Lesinurad	URAT1 inhibitor, used in combination with xanthine oxidase inhibitors	Niche role, limited market penetration
Pegloticase	IV infusion, for refractory gout	High cost, limited to severe cases

3. Patent Expiry and Generic Competition

Patent expiry in Europe and the US around 2025-2027 will likely intensify price erosion and market saturation.

4. Clinical Safety Data

Ongoing studies (e.g., FAST trial) have yet to definitively resolve safety concerns, influencing prescriber confidence.

---

Financial Trajectory and Future Outlook

Revenue Projections (2023-2030)

Year	Revenues (USD millions)	Comments
2023	~$550–$600	Post-security impact; cautious growth
2025	~$400–$500	Patent expiration effects; generic entry start
2027	~$300–$400	Increased competition, market contraction
2030	~$250–$350	Market stabilization, niche positioning

The decline reflects regulatory impacts, patent cliffs, and market share erosion.

Key Drivers for Future Revenue

• Specialized niches: Patients contraindicated for allopurinol or intolerant.
• Combination therapies: Potential with uricosurics, novel agents.
• Market expansion: Increasing use in Asian markets with rising gout prevalence.
• Cost management: Generic versions may facilitate affordability but challenge profitability.

---

Comparative Analysis: Febuxostat vs. Competitors

Attribute	Febuxostat	Allopurinol	Lesinurad	Pegloticase
Efficacy	High	Proven, effective	Adjunct therapy	Refractory gout treatment
Safety Profile	Cardiovascular concerns (boxed warning)	Tolerability issues, hypersensitivity	Limited data	Infusion reactions
Cost (approximate)	Moderate to high	Low	Moderate	Very high
Patent Status	Expired (Europe), imminent expiration	Patent in the US, expired elsewhere	Patent pending	Patent pending

---

Strategic Opportunities and Risks

Opportunities	Risks
Expanding into emerging markets with rising gout prevalence	Overshadowed by safety warnings and patent expiration
Developing safer formulations or combination therapies	Regulatory bans or restrictions due to safety profile
Collaborating on personalized medicine approaches	Market skepticism post regulatory alerts
Engaging in post-marketing studies to address safety concerns	Competitive pressure from novel agents

---

Conclusion: The Future Path for Febuxostat

While febuxostat remains a critical component in gout management, its market trajectory hinges on balancing efficacy with safety. Regulatory constraints and patent expirations are expected to decrease revenues, yet niche applications, especially in patients intolerant to allopurinol, sustain its relevance. Strategic innovation, stringent safety profiling, and market expansion in emerging economies will be vital to optimizing its long-term financial outlook.

---

Key Takeaways

• Regulatory and safety issues significantly influence febuxostat's global market share, with safety warnings dampening growth prospects.
• Patent losses projected around 2025–2027 will accelerate generic competition, driving prices downward.
• Market growth will rely on emerging markets and niche patient segments rather than broad expansion.
• Emerging therapies and evolving clinical evidence could further redefine the competitive landscape.
• Stakeholders should focus on safety data transparency, cost-effective formulations, and targeted marketing to sustain value.

---

FAQs

1. How has safety concern influenced febuxostat's prescribing trends?
Post-2019 FDA boxed warnings and similar EMA alerts have led to cautious prescribing, impacting sales especially among high cardiovascular risk populations.

2. What is the timeline for patent expiration and its implications?
Patent expiry in Europe is expected by 2025 and in the US by 2027, likely increasing generic availability and reducing revenue margins.

3. Are there ongoing clinical trials to address febuxostat’s safety profile?
Yes. The FAST trial and similar studies are evaluating cardiovascular risks, aiming to clarify safety and potentially reshape prescribing guidelines.

4. How does febuxostat compare with allopurinol in efficacy?
While both effectively lower uric acid, febuxostat demonstrates superior uric acid reduction in some patient subsets, but safety concerns impede its broader use.

5. What are the emerging therapeutic alternatives impacting febuxostat’s market?
Agents like lesinurad (URAT1 inhibitors), pegloticase, and newer biologics are carving out niche roles, potentially replacing febuxostat in refractory or contraindicated cases.

---

References

1. FDA Drug Safety Communication. Febuxostat (Uloric) and the risk of heart-related death, 2019.
2. European Medicines Agency (EMA). Assessment report on febuxostat, 2021.
3. Global Epidemiology Review. Gout prevalence and incidence data, 2020.
4. MarketResearch.com. Gout therapeutics market analysis, 2022.
5. ClinicalTrials.gov. Ongoing and completed studies on febuxostat safety and efficacy.

---

This analysis aims to guide pharmaceutical stakeholders, healthcare providers, and investment professionals in strategic decision-making regarding febuxostat’s market prospects.